Moreover, our results with the GRP94-specific inhibitor PU-WS13 highlight a link between GRP94 and the number of CD206+ M2-like macrophages, the intratumoral content of collagen, the number of infiltrating CD8+ cells, and the development of the tumor. The gene discussed is MRC1; the disease is neoplasm.